Division of Science, New York University Abu Dhabi, Abu Dhabi, UAE.
Division of Engineering, New York University Abu Dhabi, Abu Dhabi, UAE.
Artif Organs. 2021 Jul;45(7):652-664. doi: 10.1111/aor.13913. Epub 2021 Feb 27.
Cardiovascular disease has been the leading cause of death globally for the past 15 years. Following a major cardiac disease episode, the ideal treatment would be the replacement of the damaged tissue, due to the limited regenerative capacity of cardiac tissues. However, we suffer from a chronic organ donor shortage which causes approximately 20 people to die each day waiting to receive an organ. Bioprinting of tissues and organs can potentially alleviate this burden by fabricating low cost tissue and organ replacements for cardiac patients. Clinical adoption of bioprinting in cardiovascular medicine is currently limited by the lack of systematic demonstration of its effectiveness, high costs, and the complexity of the workflow. Here, we give a concise review of progress in cardiovascular bioprinting and its components. We further discuss the challenges and future prospects of cardiovascular bioprinting in clinical applications.
在过去的 15 年中，心血管疾病一直是全球范围内的主要死亡原因。在经历了一次重大的心脏疾病发作后，由于心脏组织的再生能力有限，理想的治疗方法是替换受损的组织。然而，我们长期面临着慢性器官捐献短缺的问题，这导致每天大约有 20 人在等待器官移植时死亡。通过生物打印组织和器官，可以为心脏患者制造低成本的组织和器官替代品，从而潜在地缓解这一负担。生物打印在心血管医学中的临床应用目前受到缺乏系统有效性证明、成本高和工作流程复杂的限制。在这里，我们简要回顾了心血管生物打印及其组成部分的进展。我们进一步讨论了心血管生物打印在临床应用中的挑战和未来前景。
